150 related articles for article (PubMed ID: 20551957)
1. Increased circulating cell signalling phosphoproteins in sera are useful for the detection of pancreatic cancer.
Takano S; Sogawa K; Yoshitomi H; Shida T; Mogushi K; Kimura F; Shimizu H; Yoshidome H; Ohtsuka M; Kato A; Ishihara T; Tanaka H; Yokosuka O; Nomura F; Miyazaki M
Br J Cancer; 2010 Jul; 103(2):223-31. PubMed ID: 20551957
[TBL] [Abstract][Full Text] [Related]
2. Identification of Serum Biomarker Panels for the Early Detection of Pancreatic Cancer.
Song J; Sokoll LJ; Pasay JJ; Rubin AL; Li H; Bach DM; Chan DW; Zhang Z
Cancer Epidemiol Biomarkers Prev; 2019 Jan; 28(1):174-182. PubMed ID: 30333219
[TBL] [Abstract][Full Text] [Related]
3. Serum protein signatures differentiating autoimmune pancreatitis versus pancreatic cancer.
Felix K; Hauck O; Fritz S; Hinz U; Schnölzer M; Kempf T; Warnken U; Michel A; Pawlita M; Werner J
PLoS One; 2013; 8(12):e82755. PubMed ID: 24349355
[TBL] [Abstract][Full Text] [Related]
4. Trefoil factor(s) and CA19.9: A promising panel for early detection of pancreatic cancer.
Jahan R; Ganguly K; Smith LM; Atri P; Carmicheal J; Sheinin Y; Rachagani S; Natarajan G; Brand RE; Macha MA; Grandgenett PM; Kaur S; Batra SK
EBioMedicine; 2019 Apr; 42():375-385. PubMed ID: 30956167
[TBL] [Abstract][Full Text] [Related]
5. Usefulness of MALDI-TOF/MS identification of low-MW fragments in sera for the differential diagnosis of pancreatic cancer.
Padoan A; Seraglia R; Basso D; Fogar P; Sperti C; Moz S; Greco E; Marchet A; de Manzoni G; Zambon CF; Navaglia F; Cristadoro L; Di Chiara A; Nitti D; Pedrazzoli S; Pavanello G; Plebani M
Pancreas; 2013 May; 42(4):622-32. PubMed ID: 23271396
[TBL] [Abstract][Full Text] [Related]
6. Validation of four candidate pancreatic cancer serological biomarkers that improve the performance of CA19.9.
Makawita S; Dimitromanolakis A; Soosaipillai A; Soleas I; Chan A; Gallinger S; Haun RS; Blasutig IM; Diamandis EP
BMC Cancer; 2013 Sep; 13():404. PubMed ID: 24007603
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags.
Sogawa K; Takano S; Iida F; Satoh M; Tsuchida S; Kawashima Y; Yoshitomi H; Sanda A; Kodera Y; Takizawa H; Mikata R; Ohtsuka M; Shimizu H; Miyazaki M; Yokosuka O; Nomura F
Br J Cancer; 2016 Oct; 115(8):949-956. PubMed ID: 27657339
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA biomarkers in whole blood for detection of pancreatic cancer.
Schultz NA; Dehlendorff C; Jensen BV; Bjerregaard JK; Nielsen KR; Bojesen SE; Calatayud D; Nielsen SE; Yilmaz M; Holländer NH; Andersen KK; Johansen JS
JAMA; 2014 Jan 22-29; 311(4):392-404. PubMed ID: 24449318
[TBL] [Abstract][Full Text] [Related]
9. Quantitative analysis of castration resistant prostate cancer progression through phosphoproteome signaling.
Lescarbeau RM; Kaplan DL
BMC Cancer; 2014 May; 14():325. PubMed ID: 24885093
[TBL] [Abstract][Full Text] [Related]
10. Differential diagnosis between chronic pancreatitis and pancreatic cancer: value of the detection of KRAS2 mutations in circulating DNA.
Maire F; Micard S; Hammel P; Voitot H; Lévy P; Cugnenc PH; Ruszniewski P; Puig PL
Br J Cancer; 2002 Aug; 87(5):551-4. PubMed ID: 12189555
[TBL] [Abstract][Full Text] [Related]
11. Development of serum parameters panels for the early detection of pancreatic cancer.
Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
[TBL] [Abstract][Full Text] [Related]
12. Periostin and CA242 as potential diagnostic serum biomarkers complementing CA19.9 in detecting pancreatic cancer.
Dong D; Jia L; Zhang L; Ma N; Zhang A; Zhou Y; Ren L
Cancer Sci; 2018 Sep; 109(9):2841-2851. PubMed ID: 29945294
[TBL] [Abstract][Full Text] [Related]
13. Serum Concentrations of Selenium and Copper in Patients Diagnosed with Pancreatic Cancer.
Lener MR; Scott RJ; Wiechowska-Kozłowska A; Serrano-Fernández P; Baszuk P; Jaworska-Bieniek K; Sukiennicki G; Marciniak W; Muszyńska M; Kładny J; Gromowski T; Kaczmarek K; Jakubowska A; Lubiński J
Cancer Res Treat; 2016 Jul; 48(3):1056-64. PubMed ID: 26727715
[TBL] [Abstract][Full Text] [Related]
14. Applicative Value of Serum CA19-9, CEA, CA125 and CA242 in Diagnosis and Prognosis for Patients with Pancreatic Cancer Treated by Concurrent Chemoradiotherapy.
Gu YL; Lan C; Pei H; Yang SN; Liu YF; Xiao LL
Asian Pac J Cancer Prev; 2015; 16(15):6569-73. PubMed ID: 26434876
[TBL] [Abstract][Full Text] [Related]
15. Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity.
Madhavan B; Yue S; Galli U; Rana S; Gross W; Müller M; Giese NA; Kalthoff H; Becker T; Büchler MW; Zöller M
Int J Cancer; 2015 Jun; 136(11):2616-27. PubMed ID: 25388097
[TBL] [Abstract][Full Text] [Related]
16. Discriminating patients with early-stage pancreatic cancer or chronic pancreatitis using serum electrospray mass profiling.
Hocker JR; Postier RG; Li M; Lerner MR; Lightfoot SA; Peyton MD; Deb SJ; Baker CM; Williams TL; Hanas RJ; Stowell DE; Lander TJ; Brackett DJ; Hanas JS
Cancer Lett; 2015 Apr; 359(2):314-24. PubMed ID: 25637792
[TBL] [Abstract][Full Text] [Related]
17. Progress and potential of exosome analysis for early pancreatic cancer detection.
Erb U; Zöller M
Expert Rev Mol Diagn; 2016 Jul; 16(7):757-67. PubMed ID: 27206554
[TBL] [Abstract][Full Text] [Related]
18. Comparative study of CA242 and CA19-9 for the diagnosis of pancreatic cancer.
Kawa S; Tokoo M; Hasebe O; Hayashi K; Imai H; Oguchi H; Kiyosawa K; Furuta S; Homma T
Br J Cancer; 1994 Sep; 70(3):481-6. PubMed ID: 8080734
[TBL] [Abstract][Full Text] [Related]
19. Nerve growth factor exerts differential effects on the growth of human pancreatic cancer cells.
Zhu ZW; Friess H; Wang L; Bogardus T; Korc M; Kleeff J; Büchler MW
Clin Cancer Res; 2001 Jan; 7(1):105-12. PubMed ID: 11205897
[TBL] [Abstract][Full Text] [Related]
20. Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics.
Yoneyama T; Ohtsuki S; Honda K; Kobayashi M; Iwasaki M; Uchida Y; Okusaka T; Nakamori S; Shimahara M; Ueno T; Tsuchida A; Sata N; Ioka T; Yasunami Y; Kosuge T; Kaneda T; Kato T; Yagihara K; Fujita S; Huang W; Yamada T; Tachikawa M; Terasaki T
PLoS One; 2016; 11(8):e0161009. PubMed ID: 27579675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
